Limitations of IL-2 and Rapamycin in Immunotherapy of Type 1 Diabetes

Administration of low-dose interleukin-2 (IL-2) alone or combined with rapamycin (RAPA) prevents hyperglycemia in NOD mice. Also, low-dose IL-2 cures recent-onset type 1 diabetes (T1D) in NOD mice, partially by boosting pancreatic regulatory T cells (T(reg) cells). These approaches are currently bei...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Baeyens, Audrey, Pérol, Louis, Fourcade, Gwladys, Cagnard, Nicolas, Carpentier, Wassila, Woytschak, Janine, Boyman, Onur, Hartemann, Agnès, Piaggio, Eliane
Format: Artigo
Jezik:Inglês
Izdano: American Diabetes Association 2013
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3749335/
https://ncbi.nlm.nih.gov/pubmed/23670972
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db13-0214
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki